Literature DB >> 18062896

Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects.

Veena Raizada1, Betty Skipper, Wentao Luo, Jeffrey Griffith.   

Abstract

The renin-angiotensin system (RAS) is a hormonal system that controls body fluid volume, blood pressure, and cardiovascular function in both health and disease. Various tissues, including the heart and kidneys, possess individual locally regulated RASs. In each RAS, the substrate protein angiotensinogen is cleaved by the peptidases renin and angiotensin-converting enzyme to form the biologically active product angiotensin II, which acts as an intracrine cardiac and renal hormone. The components of each RAS, including aldosterone (ALDO), may be produced locally and/or may be delivered by or sequestered from the circulation. Overactivity of the cardiac RAS has been associated with cardiac diseases, including cardiac hypertrophy due to volume and/or pressure overload, heart failure, coronary artery disease with myocardial infarction, and hypertension. Overactivity of the renal RAS has been associated with various kidney diseases, including nephropathies and renal artery stenosis. The principal effects of an overactive RAS include the generation of reactive oxygen species, which leads to "oxidative stress," activation of the nuclear transcription factor kappaB, and stimulation of pathways and genes that promote vasoconstriction, endothelial dysfunction, cell hypertrophy, fibroblast proliferation, inflammation, excess extracellular matrix deposition, atherosclerosis, and thrombosis. It has been suggested that oxidative stress is the central mechanism underlying the pathogenesis of RAS-related and ALDO-related chronic cardiovascular and renal tissue injury and of cardiac arrhythmias and conduction disturbances.

Entities:  

Mesh:

Year:  2007        PMID: 18062896     DOI: 10.2310/6650.2007.00020

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  25 in total

1.  Maternal diabetes programs hypertension and kidney injury in offspring.

Authors:  Yun-Wen Chen; Isabelle Chenier; Stella Tran; Michael Scotcher; Shiao-Ying Chang; Shao-Ling Zhang
Journal:  Pediatr Nephrol       Date:  2010-04-27       Impact factor: 3.714

2.  Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion.

Authors:  Ping Lu; Lifen Yuan; Yuqiang Wang; Qin Du; Jing Sheng
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

3.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

4.  Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.

Authors:  Kameswaran Ravichandran; Abdullah Ozkok; Qian Wang; Adam E Mullick; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2014-12-23

5.  Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells.

Authors:  Zhengchao Wang; Lin Tang; Qing Zhu; Fan Yi; Fan Zhang; Pin-Lan Li; Ningjun Li
Journal:  Kidney Int       Date:  2010-09-29       Impact factor: 10.612

6.  Regulation of a novel angiotensin II precursor, proangiotensin-12, in the tissues by blockade of the renin-angiotensin system.

Authors:  Ryousuke Satou; Hiroyuki Kobori
Journal:  Hypertens Res       Date:  2011-10-13       Impact factor: 3.872

Review 7.  Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.

Authors:  Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

8.  Adipose tissue-specific dysregulation of angiotensinogen by oxidative stress in obesity.

Authors:  Sadanori Okada; Chisayo Kozuka; Hiroaki Masuzaki; Shintaro Yasue; Takako Ishii-Yonemoto; Tomohiro Tanaka; Yuji Yamamoto; Michio Noguchi; Toru Kusakabe; Tsutomu Tomita; Junji Fujikura; Ken Ebihara; Kiminori Hosoda; Hiroshi Sakaue; Hiroyuki Kobori; Mira Ham; Yun Sok Lee; Jae Bum Kim; Yoshihiko Saito; Kazuwa Nakao
Journal:  Metabolism       Date:  2010-01-04       Impact factor: 8.694

Review 9.  Management of renal artery stenosis: What does the experimental evidence tell us?

Authors:  Mohammed Al-Suraih; Joseph Peter Grande
Journal:  World J Cardiol       Date:  2014-08-26

Review 10.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.